Anne Tomalin

Vice President, Quality, Regulatory & Safety

Innomar Strategies

Anne Tomalin, BA, B.Sc., joined Innomar in 2018 following the acquisition of TPIreg. With over 40 years of experience in the pharmaceutical industry, she is a recognized leader in Regulatory Affairs, Quality Assurance, and Safety. As the founder and president at TPIreg, she consulted with pharmaceutical companies in Canada and internationally and is a recognized leader and speaker on regulatory, including biological products and rare disease. At Innomar she strategically and operationally leads a diverse team focused on Regulatory Affairs (RA), QA (GMP focused), and Safety (medical information and pharmacovigilance) to optimize client launch planning and operations throughout the product lifecycle.

Before founding TPIreg, Anne worked for Optimum Insight, where she was responsible for overseeing all of the regulatory, quality, and pharmacovigilance activities provided by the company. Anne also founded and led Canada’s largest regulatory consulting company, CanReg Inc., with a team of over 100 individuals located in Canada, the US and Europe covering registration activities across drugs, biotechnology products and medical devices in over 60 countries. Anne has a strong background in business, government, regulation and reimbursement policies.

Anne has a Bachelor of Arts and a Bachelor of Science degree from York University. She also has RAPS Certification – RAC in US, European and Canadian Regulatory Affairs. Anne has been given a Lifetime Achievement Award from the Canadian Society of Pharmaceutical Sciences.


All Sessions by Anne Tomalin

Printer Friendly See Full Agenda

Day 1: Oct 6, 2020

12:00 pm

12:00 pm

Panel Discussion

Streamlining the Path to Market: Regulatory Modernization – Is Canada a Land of Regulatory Obstacles or Opportunities?

The federal government has faced challenges in updating regulations to keep up with the modern changes to drug discovery and with market access.  The result could be viewed as an onerous regulatory burden or as regulatory clarity paving the way for future opportunities.  Take back to your team actionable insights about:

  • The benefits expected from the current federal regulatory modernization project
  • Whether perceived regulatory burdens can be alleviated or reduced
  • How greater clarity in updated regulations can translate into opportunities for market access

Learn how to reduce regulatory burden and leverage regulatory modernization into increased opportunities

Day 2: Oct 7, 2020

Day 3: Oct 8, 2020